Liver Disease Therapeutics Market Size & Share 2025 - 2034

Liver Disease Therapeutics Market Size

The global liver disease therapeutics market size was valued at USD 24.5 billion in 2024. The market is anticipated to grow from USD 25.9 billion in 2025 to USD 50.4 billion in 2034, growing at a CAGR of 7.7% from 2025 to 2034. The market is experiencing significant growth primarily due to the increasing global prevalence of liver diseases across different age demographics.

For example, as per the National Institute of Health (NIH), liver disease accounts for 2 million deaths annually and is responsible for 4% of all deaths (1 out of every 25 deaths worldwide). Excessive alcohol consumption, viral hepatitis (like hepatitis A, B, and C), non-alcoholic fatty liver disease (NAFLD), and certain genetic conditions are some of the common reasons for the high incidence of liver diseases.
 

Another key driver is the aging population worldwide. With increased life expectancy, age-related conditions, including liver disorders, are increasingly prevalent. The elderly are predisposed to chronic liver disease because of long-term exposure to risk factors such as alcohol, drugs, and metabolic syndrome. This population trend adds to a wider market for liver disease drugs, as global healthcare systems adapt to cater to the needs of the elderly population.
 

Also, the market growth is supported by the improvement in diagnostic technologies such as PCR testing and cancer diagnostics, which have enhanced the early diagnosis of several liver diseases and consequently increased the market demand. The development of novel liver drugs further supports the market growth. For instance, a breakthrough in liver disease treatment came with the FDA approval of Rezdiffra (resmetirom) in March 2024, marking the first drug specifically for non-alcoholic steatohepatitis (NASH) with liver scarring (fibrosis), but not cirrhosis. This new medication targets protein in the liver to reduce fat, inflammation, and fibrosis, and is intended to be used alongside diet and exercise. Such development and approval of new therapeutics will drive market growth.
 

Liver disease therapeutics refers to the range of medical treatments and interventions used to manage, treat, or cure diseases and disorders affecting the liver. These therapeutics include pharmaceutical drugs, biologics, and emerging therapies like gene or cell-based treatments. The goal of these medications is to reduce liver damage, manage symptoms, halt disease progression, and, in some cases, restore liver function.
 

Liver Disease Therapeutics Market Trends

• The increasing prevalence of liver diseases is a key driver propelling the growth of the market. According to the World Health Organization estimates, hepatitis infects hundreds of millions of people worldwide, whereas liver diseases such as non-alcoholic fatty liver disease (NAFLD) are currently the most prevalent chronic liver disease in most developed countries.
   
• For example, as per the Global Hepatitis Report 2024, 254 million people are living with hepatitis B and 50 million are people living with hepatitis C worldwide. Similarly, as per the NIH, NAFLD (non-alcoholic fatty liver disease) affects a significant portion of the global population in 2024, with an estimated prevalence of around 30.2%. Liver cancer, meanwhile, ranks as the sixth most common cancer worldwide.
   
• This growing disease burden directly results in increased demand for viable therapeutic options, from antiviral drugs for hepatitis to novel treatments for end-stage liver fibrosis and cirrhosis.
   
• In response, pharmaceutical companies and healthcare providers are ramping up investments in drug development, diagnostic tools, and early screening programs to meet increasing clinical needs.
   
• The liver disease therapeutics market is also benefiting from therapeutic advancements, especially in mRNA technology, antiviral therapies, and immune-modulating strategies. These cutting-edge approaches address the limitations of conventional protein-based and DNA-based treatments, offering new hope for managing complex and chronic liver diseases.
   
• Government support and rising healthcare expenditures further reinforce market expansion. Several countries have rolled out national hepatitis elimination programs and awareness campaigns aimed at early diagnosis and treatment. These efforts, supported by wider insurance coverage and favorable reimbursement policies, are improving patient access and boosting demand for liver disease therapeutics.
   
• Moreover, leading pharmaceutical firms are targeting high-growth emerging markets such as Asia Pacific, Latin America, and the Middle East. Countries like China, India, and Brazil, with their increasing liver disease prevalence and improving healthcare infrastructure, present significant commercial potential. To capitalize on this, global players are adopting region-specific strategies, including local manufacturing, regulatory adaptation, and strategic alliances.
   

Liver Disease Therapeutics Market Analysis

Based on the product, the global market is segmented into antiviral drugs, vaccines, chemotherapy, targeted therapy, immunosuppressants, immunoglobulins, corticosteroids, and other products. The antiviral drugs segment accounted for the highest market share and was valued at USD 9.7 billion in 2024.
 

• The antiviral drugs segment commands the largest share in the market owing to the high prevalence of viral hepatitis, especially hepatitis B and C. These infections are among the leading causes of chronic liver disease, cirrhosis, and hepatocellular carcinoma.
   
• High prevalence of hepatitis has generated long-term demand for high-performing antiviral therapies, particularly with the emergence of direct-acting antivirals (DAAs), which are characterized by high cure rates and fewer side effects.
   
• Their performance of yielding sustained virologic response (SVR) in a relatively short period of treatment has revolutionized the treatment of hepatitis C, making the segment hold a strong market presence.
   
• Advancements in antiviral therapy have also been key to growing this segment's market size. The launch of next-generation antivirals with enhanced efficacy, resistance profiles, and patient compliance has facilitated increased usage in both developed and developing countries.
   
• Specifically, combination therapies targeting various points of the viral lifecycle have become the new standard of care, further enhancing the role of antivirals in liver disease management.

Learn more about the key segments shaping this market

Download Free PDF

Based on disease type, the global liver disease therapeutics market is categorized into hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders, and other disease types. The hepatitis segment dominated the market with 47.4% market share in 2024.
 

• The hepatitis segment dominates the market due to the large burden of viral hepatitis infections across the globe. High prevalence of this condition has generated high demand for successful treatments, fueling the demand for hepatitis therapeutics.
   
• Ongoing innovation in drug development has further solidified the position of the hepatitis segment. The advent of pan-genotypic regimens for hepatitis C and nucleotide analogues for hepatitis B has made treatment more accessible and patient compliance easier. They possess improved safety profiles, shorter treatment durations, and greater cure rates, which have been translated into wider use among different patient populations.
   
• Also, with continuous efforts towards constructing functional cures for hepatitis B, the pipeline remains strong, ensuring that this segment remains at the forefront of liver disease therapeutics.
   
• Further, government initiatives and international health programs focused on the eradication of hepatitis have also been important in driving this segment. Organizations such as the WHO have aggressively laid out the goal of achieving the elimination of viral hepatitis as a public health problem by 2030, leading numerous nations to launch country-level screening, vaccination, and treatment campaigns.
   
• Growing awareness, improved diagnosis, and increased access to therapy, particularly in emerging economies, are anticipated to continue to spur the dominance of the hepatitis segment in the market.
   

Based on the gender, the global liver disease therapeutics market is divided into male and female. The male segment dominated the market in 2024 and is anticipated to witness growth at a CAGR of 7.2%.
 

• The male demographic holds a dominant share in the market, primarily due to the higher incidence of liver conditions among men compared to women.
   
• Epidemiological studies consistently indicate that men are more prone to chronic liver disorders such as alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), and viral hepatitis. As a result, men represent a larger portion of the patient population requiring medical intervention, driving higher demand for liver disease treatments in this group.
   
• Biological and hormonal differences further explain this disparity. Estrogen is believed to offer a protective effect on liver function, making premenopausal women less susceptible to liver inflammation and fibrosis. In contrast, men tend to experience faster progression from NAFLD to more severe conditions like non-alcoholic steatohepatitis (NASH) and cirrhosis.
   

Based on the route of administration, the global liver disease therapeutics market is divided into oral and parenteral. The oral segment dominated the market in 2024 and is anticipated to reach USD 34.7 billion by end of 2034.
 

• Oral drugs are preferred owing to their convenience, ease of use, and high compliance by patients. Tablets and capsules are popular choices over injectable or intravenous dosage forms, for long-term therapeutic interventions related to chronic liver disorders such as hepatitis B and C, NAFLD, and cirrhosis.
   
• Also, patients can self-administer oral drugs at home without clinical visits, saving on healthcare costs and enhancing compliance with prescribed treatments.
   
• The efficacy of oral antiviral medications has further increased their adoption rates. The introduction of direct-acting antivirals (DAAs), which are only available orally, transformed the management of hepatitis C with high rates of cure, few side effects, and brief courses of therapy.
   
• In the same way that first-line therapies for hepatitis B, like tenofovir and entecavir, are oral drugs that have become the standard of practice. Therefore, the efficacy of such drugs in the treatment of viral hepatitis has popularized them and cemented the oral segment's position in liver disease therapy.
   

Based on the end use, the global liver disease therapeutics market is categorized into hospitals and clinics, ambulatory surgical centers, and other end users. The hospitals and clinics segment dominated the market in 2024 and is expected to reach USD 31.2 billion by 2034.
 

• Hospitals and clinics are the primary choice for liver disease patients due to their ability to offer comprehensive and specialized care.
   
• Liver diseases frequently necessitate multidisciplinary treatment that include diagnostics, drug therapy, monitoring, as well as surgical interventions like biopsies or transplant of the liver.
   
• Hospitals and clinics comprise the infrastructure, such as advanced imaging, laboratory work, and specialized staff, to provide quality care. Therefore, patients with moderate to serious liver conditions prefer these facilities.
   
• Furthermore, the availability of inpatient care and emergency services in hospitals and clinics adds to their strong market presence.

The North America liver disease therapeutics market dominated the global market with a market share of 38.2% in 2024.
 

The U.S. market was valued at USD 7.5 billion and USD 7.8 billion in 2021 and 2022, respectively. The market size reached USD 8.5 billion in 2024, growing from USD 8.1 billion in 2023.
 

• The U.S. leads the global market, driven by a high and growing prevalence of liver disorders such as hepatitis C, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH), largely attributed to lifestyle factors like obesity, diabetes, and alcohol consumption.
   
• According to the CDC, NAFLD now affects 38% of the U.S. population, having surged by 50% over the past three decades. This substantial patient base, coupled with increased awareness, early screening programs, and widespread access to advanced healthcare services, underpins strong market demand.
   
• Public and private insurance programs, including Medicare and Medicaid, further improve access to costly antiviral and specialty therapies.
   
• Supported by leading research institutions, specialized liver clinics, and national awareness initiatives, the U.S. continues to dominate the liver disease therapeutics space.
   

Europe liver disease therapeutics market accounted for USD 7.1 billion in 2024 and is anticipated to show considerable growth over the forecast period.
 

• Europe holds a considerable position in the global market owing to its high aging population, growing incidence of chronic liver diseases, and a well-established public health framework.
   
• Countries such as Germany, France, the U.K., and Italy are witnessing increased cases of hepatitis B and C, alcoholic liver disease, and NAFLD, driven by high alcohol consumption, obesity, and metabolic disorders.
   
• The region benefits from a strong public healthcare system and the presence of several major pharmaceutical and biotech firms focused on liver disease treatment. In Germany, the aging population was over 22% aged 65 and above in 2023, coupled with universal health coverage and streamlined reimbursement mechanisms, has created favorable conditions for market expansion.
   
• The emphasis on early detection and prevention further enhances treatment outcomes and market penetration.
   

Germany liver disease therapeutics market is anticipated to witness considerable growth over the analysis period.
 

• Aging populations, increased incidence of obesity and diabetes, and high alcohol consumption levels are some of the factors that contribute to market growth. Also, Germany's universal health coverage and permissive regulatory environment contribute to the development of the market.
   
• With universal health insurance coverage and streamlined reimbursement procedures, patients obtain extensive access to currently available treatments as well as newly approved ones.
   
• Early detection and prevention are also encouraged by the country, making timely intervention and long-term management of liver diseases more likely.
   
• Combined, these elements make Germany a prominent marketplace for liver disease therapeutics in Europe.
   

The Asia Pacific liver disease therapeutics market is expected to witness significant growth over the analysis timeframe.
 

• The Asia Pacific market for liver disease therapeutics is experiencing rapid growth due to its high population base and very growing incidence of liver diseases, especially hepatitis B and C.
   
• Countries, including China, India, and Southeast Asian nations, have a high burden of viral hepatitis due to factors such as low vaccination coverage over decades, unsafe sanitation in some parts of these nations, and vertical transmission of the virus. For example, India had over 11% of global hepatitis burden in 2022, with 35.3 million cases.
   
• Besides this, increased incidence of lifestyle-induced liver diseases such as non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease is also increasing the demand for effective treatment options in the region.
   

China liver disease therapeutics market is predicted to grow significantly over the forecast period.
 

• China is experiencing high growth in the market fueled by its huge population and high incidence of liver diseases, most notably hepatitis B.
   
• Being among the nations with the highest burden of chronic hepatitis B in the world, China has an enormous need for affordable and efficient treatments for liver disease.
   
• According to a recent estimation, approximately 75 million people in China are afflicted with hepatitis B, accounting for nearly one-third of the 254 million individuals chronically infected with HBV worldwide.
   
• Increased awareness, government-led screening and vaccination programs, and earlier diagnoses have expanded the treatment base, especially for antivirals and liver fibrosis therapies.
   

Brazil is experiencing significant growth in the Latin America liver disease therapeutics market.
 

• Brazil is witnessing rapid expansion in the liver diseases therapeutics market due to the increasing prevalence of liver-related conditions such as hepatitis, fatty liver disease, and cirrhosis.
   
• As awareness grows and diagnostic capacity improves, more patients are being diagnosed and treated, translating into a large demand for new and effective liver disease treatments.
   
• Brazil's healthcare infrastructure has seen significant investments, both from the government and private sectors, which have enhanced access to advanced treatment options.
   
• Additionally, public health campaigns aimed at preventing liver diseases, such as vaccination programs and lifestyle education, contribute to earlier diagnosis and intervention, thereby propelling market growth.
   

South Africa liver disease therapeutics market is poised to witness substantial growth in Middle East and Africa market during the forecast period.
 

• The country is experiencing rising rates of hepatitis and liver cancer, and improvements in diagnostic capabilities have led to earlier identification and treatment of liver conditions.
   
• Additionally, collaborations with global pharmaceutical firms and active clinical research are facilitating the introduction of advanced therapeutics, enhancing access to innovative treatment options and supporting the market’s expansion in the region.
   

Liver Disease Therapeutics Market Share

The global market is characterized by the presence of several players including large multinational corporations, local and regional manufacturers, and start-ups. Top 4 players such as Gilead Sciences, AbbVie, F. Hoffmann-La-Roche, and Bristol-Myers Squibb hold approximately 45% - 50% of the global market.
 

These key market players are using strategic growth initiatives such as partnerships and acquisitions, new product launches, and geographic expansion to enhance their market presence and gain competitive edge. These players focus on new innovations and develop innovative products centered on customer needs to increase their share in the rapidly growing industry.
 

Liver Disease Therapeutics Market Companies

Few of the prominent players operating in the liver disease therapeutics industry include:

• Amgen
• AbbVie
• Bristol-Myers Squibb
• Bayer
• GSK plc
• Gilead Sciences
• Hoffmann-La Roche
• Intercept Pharmaceuticals
• Johnson & Johnson Services
• Merck & Co.
• Novartis
• Pfizer
• Sanofi
• Takeda Pharmaceutical Company Limited
• Zydus Lifesciences
   
• Gilead Sciences is a key player in liver disease therapeutics, particularly known for revolutionizing hepatitis C treatment with its antiviral drugs like Sovaldi, Harvoni, and Epclusa. The company also has a strong presence in hepatitis B and is actively expanding into nonalcoholic steatohepatitis (NASH) and liver cancer. With ongoing R&D and strategic acquisitions, Gilead continues to shape the future of liver disease care worldwide.
   
• AbbVie is a key player in the market, primarily through its hepatitis C treatment, Mavyret (glecaprevir/pibrentasvir), which offers high cure rates across all major HCV genotypes. The company has leveraged strong global access strategies to expand its reach in both developed and emerging markets. AbbVie continues to invest in liver-related research, including areas like NASH and liver fibrosis, to strengthen its therapeutic portfolio.
   

Liver Disease Therapeutics Industry News

• In June 2025, AbbVie announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for MAVYRET (glecaprevir/pibrentasvir), an oral pangenotypic direct acting antiviral (DAA) therapy. It is now approved for the treatment of adults and pediatric patients three years and older with acute or chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis. With this approval, MAVYRET is the first and only DAA therapy approved to treat patients with acute HCV in eight weeks with a 96% cure rate.
   
• In March 2025, Takeda Pharmaceutical Company Limited received approval from Japan's Ministry of Health, Labour and Welfare for Livmarli (maralixibat) oral solution. The drug is indicated for treating Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC). This approval supports Takeda’s focus on addressing rare pediatric liver diseases with high unmet needs.
   
• In August 2024, the U.S. FDA approved Gilead’s liver disease drug seladelpar (Pivlaz) for treating primary biliary cholangitis. The approval followed positive Phase 3 ENHANCE trial results showing significant efficacy. Gilead gained the drug through its USD 4.3 billion acquisition of CymaBay Therapeutics earlier in the year.
   

The liver disease therapeutics market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Antiviral drugs
• Vaccines
• Chemotherapy
• Targeted therapy
• Immunosuppressants
• Immunoglobulins
• Corticosteroids
• Other products

Market, By Disease Type

• Hepatitis
• Autoimmune diseases
• Non-alcoholic fatty liver disease (NAFLD)
• Cancer
• Genetic disorders
• Other disease types

Market, By Gender

• Male
• Female

Market, By Route of Administration

• Oral
• Parenteral

Market, By End Use

• Hospitals and clinics
• Ambulatory surgical centers
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE